TrialAnticancer research2016

A Phase II Study of BEZ235 in Patients with Everolimus-resistant, Advanced Pancreatic Neuroendocrine Tumours.

Nicola Fazio et al.PubMed ↗Full text ↗

No numbers read from the abstract.